A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer. Li S, Zhang Y, Yang R, Yang Q, et al. Anticancer Drugs 2025 Jan 29. doi: 10.1097/CAD.0000000000001698.

Read + Share

Amedeo Smart

Independent Medical Education

Li S, Zhang Y, Yang R, Yang Q, et al. A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer. Anticancer Drugs 2025 Jan 29. doi: 10.1097/CAD.0000000000001698.
PMID: 39878099